A new species of Archaeoryctes from the Middle Paleocene of China and the phylogenetic diversification of Didymoconidae

Didymoconidae are an enigmatic group of Asian endemic insectivorous mammals. We describe the new didymoconid species Archaeoryctes wangi sp. nov. from the Upper Member of the Wanghudun Formation (Middle Paleocene). This new species from the Qianshan Basin (Anhui Province, China) forms an interesting geographical intermediate between A. notialis from South China and A. borealis and A. euryalis from the Mongolian Plateau. To better understand the origin and evolutionary diversification of Didymoconidae, we performed a cladistic and stratocladistic study of the Didymoconidae and various outgroups. This study of dental material did not resolve the higher level affinities of Didymoconidae, but confirms the validity of the family and its distinctiveness from the morphologically similar Sarcodontidae. Moreover, our results corroborate the current didymoconid classification with the distinction of three subfamilies: “Ardynictinae”, Kennatheriinae and Didymoconinae; “Ardynictinae” are a paraphyletic stemgroup for the two other subfamilies. Our results suggest three distinct didymoconid radiations: (1) primitive ardynictines appeared in South China from the start of the Nongshanian; their evolution continues on the Mongolian Plateau with (2) the radiation of more evolved ardynictines and kennatheriines at the start of the Middle Eocene Arshantan and (3) the origin of didymoconines at the start of the Late Eocene Ergilian

Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance

Clinical antimicrobial susceptibility breakpoints are used to predict the clinical outcome of antimicrobial treatment. In contrast, microbiologic breakpoints are used to identify isolates that may be categorized as susceptible when applying clinical breakpoints but harbor resistance mechanisms that result in their reduced susceptibility to the agent being tested. Currently, the National Committee for Clinical Laboratory Standards (NCCLS) guidelines utilize clinical breakpoints to characterize the activity of the fluoroquinolones against Streptococcus pneumoniae. To determine whether levofloxacin breakpoints can identify isolates that harbor recognized resistance mechanisms, we examined 115 S. pneumoniae isolates with a levofloxacin MIC of >2 μg/mL for first-step parC mutations. A total of 48 (59%) of 82 isolates with a levofloxacin MIC of 2 μg/mL, a level considered susceptible by NCCLS criteria, had a first-step mutation in parC. Whether surveillance programs that use levofloxacin data can effectively detect emerging resistance and whether fluoroquinolones can effectively treat infections caused by such isolates should be evaluated